Is there evidence that radiotherapy to less than all sites of oligometastatic prostate cancer is beneficial?

The ORIOLE trial referenced above helps to answer this question. Within the SBRT arm (n=36), patients received PSMA PET, however, the treating rad oncs were blinded to the result and patients were "consolidated" based on conventional imaging. Treatment plans were then reviewed and compared to PSMA, ...

STAMPEDE (Parker et al., PMID 30355464; Ali et al., PMID 33599706) reported benefit of prostate-only radiotherapy for patients with low metastatic burden with the greatest benefit for M1a (non-regional nodes) or 3 or fewer bone metastases without visceral metastases. For patients with prior prostate...